Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$14.13M+101.87%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Nicholas T. Curtis
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 150
- Beta
- 1.03
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 0.66
Financials
Revenue
$14.13M+101.9%Net Income
$-4.72MEBITDA
$-3.67MFree Cash Flow
$-978.0KEPS (diluted)
$-0.38Shares Outstanding (diluted)
12.40M+1058.7%Operating Expenses
$9.37MCash & Debt
$12.62MReturn of Capital
$0.00Revenue by Segment (annual)
$51.66MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $58.44M | $-34.28M | $-2.87 |
| 2024 | $53.49M | $-31.40M | $-2.73 |
| 2023 | $42.16M | $-14.38M | $-1.31 |
| 2022 | $35.36M | $-19.91M | $-1.96 |
| 2021 | $34.46M | $-19.60M | $-2.10 |
| 2020 | $26.38M | $-19.77M | $-1.81 |
| 2019 | $30.53M | $-14.66M | $-1.57 |
| 2018 | $24.39M | $-12.59M | $-11.77 |
Valuation
LNSRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+200.00%Social Signal Score
Mentions (6)
- Newsmarketbeat.com·12d ago·Negative
LENSAR Q3 Earnings Call Highlights LENSAR NASDAQ: LNSR reported a slight decline in third-quarter revenue as lower sales of its cataract surgery systems offset growth in procedure and other recurring revenue. The company said its installed base and procedure volume continued to expand, while its operating loss narrowed from a year earlier.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
LENSAR, Inc. (LNSR) Q3 2026 Earnings Call Transcript LENSAR, Inc. (LNSR) Q3 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
…aser Installed Base Reaches 450 Systems; ALLY System Installed Base Expands 22% Year Over Year ORLANDO, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2026 and provided an update on key operational initiatives.
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
LENSAR® to Report Third Quarter 2026 Results on November 10th, 2026 ORLANDO, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's third quarter 2026 financial results will be released before market open on Tuesday, November 10, 2026.
View source ↗ - Newsmarketbeat.com·101d ago·Neutral
LENSAR Q2 Earnings Call Highlights LENSAR NASDAQ: LNSR reported second-quarter 2026 revenue growth of 18% as the company continued to rebuild commercial momentum following the termination of its proposed merger with Alcon near the end of the first quarter.
View source ↗ - Newsglobenewswire.com·101d ago·Neutral
…lion Total Laser Installed Base Climbs to 445 Systems, Driven by 30% Growth in ALLY Placements ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2026 and provided an update on key operational initiatives.
View source ↗
Earnings
Tue, Mar 9(in 4 months)
Consensus estimate $-0.11 per share
Typical surprise -87.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.38 vs $-0.10miss
- Thu, Aug 13$0.10 vs $-0.17beat
- Fri, May 8$1.56 vs $0.18beat
- Tue, Mar 31$-0.12 vs $-0.07miss
- Thu, Nov 6$-0.31 vs $-0.10miss
- Thu, Aug 7$-0.15 vs $-0.08miss
Estimates and results for LNSR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LNSR officers and directors.
- Bought
- $167k
- Sold
- $170k
20 trades
2 trades
- O'farrell Elizabeth G.sold
- O'farrell Elizabeth G.sold
- Winer Gary Mbought
- Winer Gary Mbought
- Winer Gary Mbought
- Winer Gary Mbought
- Winer Gary Mbought
- Winer Gary Mbought
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LNSR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
